Garri Zmudze Insights

CONTRIBUTED CONTENT

Garri contributes op-eds and original content for leading outlets across web3, health, startups, and more.

LinkedIn: Women at the forefront of longevity: Celebrating and investing in an inclusive future

Women help build a more inclusive longevity space. Their dedication, talent, and ability to make an impact stand out.

Contributed Content

LinkedIn: Women at the forefront of longevity: Celebrating and investing in an inclusive future

Cointelegraph: Generative AI can deliver life-changing disease treatments

Generative AI can improve our healthcare system with faster drug discovery and treat devastating diseases.

Contributed Content

Cointelegraph: Generative AI can deliver life-changing disease treatments

LinkedIn: Irresponsible chatbot AI, meet restrained biotech AI

AI has the power to level up our health and lifespans like never before. Leaders in the biotech sector have been working hard to ensure the responsible and ethical use of AI.

Contributed Content

LinkedIn: Irresponsible chatbot AI, meet restrained biotech AI

EXPERT COMMENTARY

Garri is a leading voice for trending topics in the field of health and investing.

AgeTech World: Longevity Will Never Be a Magic Pill That Will Make Us Younger

I share my drive and LongeVC's strategic investments in advancing an ageless future, emphasising the need for standardised longevity practises and systemic health economics reform

Expert Commentary

AgeTech World: Longevity Will Never Be a Magic Pill That Will Make Us Younger

Wall Street Journal: The Clues to Longer Life That Are Coming From Dogs

Scientists are researching dog aging, including supplement trials and genetic analysis, to unlock a greater understanding of human longevity.

Expert Commentary

Wall Street Journal: The Clues to Longer Life That Are Coming From Dogs

DealStreet Asia: LongeVC Targets $250M for Fund II, Bets on Opportunities in Asia’s Longevity Tech Growth

In a recent interview for DealStreet Asia, Garri discussed the international longevity and biotech investing landscape and provided insights on LongeVC’s planned Fund II.

Expert Commentary

DealStreet Asia: LongeVC Targets $250M for Fund II, Bets on Opportunities in Asia’s Longevity Tech Growth

ANNOUNCEMENT

Stay up-to-date with the latest from Garri and the companies within his realm.

Longevity.Technology: The time is right for specialist Longevity investment

Garri Zmudze, Sergey Jakimov, and Ilya Suharenko launch a new fund for longevity research: LongeVC.

Longevity.Technology: The time is right for specialist Longevity investment

Longevity.Technology: Basepaws acquisition – exploring longevity beyond human health

Garri was an angel investor in pet health company Basepaws. Its acquisition offers promising insights into the future of human longevity.

Longevity.Technology: Basepaws acquisition – exploring longevity beyond human health

ARDD: Decentralized science and blockchain in aging research

Garri explains the Longevity Science Foundation's work as a nonprofit supporting a decentralized and transparent future of longevity research.

ARDD: Decentralized science and blockchain in aging research

ALL RESOURCES

Content at the cutting-edge of health and technology.

Longevity.Technology: The time is right for specialist Longevity investment

Garri Zmudze, Sergey Jakimov, and Ilya Suharenko launch a new fund for longevity research: LongeVC.

Longevity.Technology: The time is right for specialist Longevity investment

Longevity.Technology: Basepaws acquisition – exploring longevity beyond human health

Garri was an angel investor in pet health company Basepaws. Its acquisition offers promising insights into the future of human longevity.

Longevity.Technology: Basepaws acquisition – exploring longevity beyond human health

ARDD: Decentralized science and blockchain in aging research

Garri explains the Longevity Science Foundation's work as a nonprofit supporting a decentralized and transparent future of longevity research.

ARDD: Decentralized science and blockchain in aging research

Forbes: Meet a VC on a mission to support women in longevity

Garri leads LongeVC to invest in diverse founders that will ensure a representative future of longevity and biotech.

Forbes: Meet a VC on a mission to support women in longevity

LongeVC Backs Interface Biosciences for Advancing Inflammatory Disease Drug Development with AI-Enabled Platform

LongeVC invests in Interface Biosciences, securing $3 million for pioneering pharmaceutical development from bacterial natural products, marking a strategic advancement towards critical IND-enabling studies

Expert Commentary

LongeVC Backs Interface Biosciences for Advancing Inflammatory Disease Drug Development with AI-Enabled Platform

LongeVC Supports UNP's $32M Series A Funding for AI-Driven Macrocycle Drug Development

LongeVC Partakes in UNP's $32 Million Series A Funding, Boosting AI-Driven Macrocycle Innovation for Oncology and Beyond

LongeVC Supports UNP's $32M Series A Funding for AI-Driven Macrocycle Drug Development

Garri Zmudze Speaking at The Asia Summit on Global Health (ASGH) in Hong Kong

Garri Zmudze will attend this year’s Asia Summit on Global Health (ASGH 2024) as a speaker and investor. He will participate in the "New Frontiers in Healthy Ageing" panel.

Garri Zmudze Speaking at The Asia Summit on Global Health (ASGH) in Hong Kong

Summary of LongeVC’s Investments in Q1 and Q2

As we’re getting to the end of Q2, we prepared a quick summary of all the new additions to LongeVC’s investment portfolio.

Summary of LongeVC’s Investments in Q1 and Q2

LongeVC’s Q3 & Q4 2024: Investments and Portfolio Updates

LongeVC shares Q3 & Q4 2024 updates, including new investments in Glyphic Bio and Proton Intelligence, as well as key portfolio developments from Turn Bio and Longenesis.

LongeVC’s Q3 & Q4 2024: Investments and Portfolio Updates

BioSpectrum: Seeking the 'fountain of youth'

Garri founded the Longevity Science Foundation to fund the diverse treatments contributing to human longevity.

Expert Commentary

BioSpectrum: Seeking the 'fountain of youth'